Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

  1. Dimopoulos, M.A.
  2. Richardson, P.G.
  3. Bahlis, N.J.
  4. Grosicki, S.
  5. Cavo, M.
  6. Beksaç, M.
  7. Legieć, W.
  8. Liberati, A.M.
  9. Goldschmidt, H.
  10. Belch, A.
  11. Magen, H.
  12. Larocca, A.
  13. Laubach, J.P.
  14. Petrucci, M.T.
  15. Reece, D.
  16. White, D.
  17. Mateos, M.-V.
  18. Špička, I.
  19. Lazaroiu, M.
  20. Berdeja, J.
  21. Kaufman, J.L.
  22. Jou, Y.-M.
  23. Ganetsky, A.
  24. Popa McKiver, M.
  25. Lonial, S.
  26. Weisel, K.
  27. Erakutsi egile guztiak +
Aldizkaria:
The Lancet. Haematology

ISSN: 2352-3026

Argitalpen urtea: 2022

Alea: 9

Zenbakia: 6

Orrialdeak: e403-e414

Mota: Artikulua

DOI: 10.1016/S2352-3026(22)00103-X GOOGLE SCHOLAR